1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Telix Pharmaceuticals is targeting rapid global expansion in radiopharmaceuticals, with CEO Chris Behrenbruch outlining how Telix Pharmaceuticals (ASX: TLX) is positioning itself as a leading radiopharmaceutical company focused on both diagnostic and therapeutic oncology products. The lead prostate cancer imaging agent, Illuccix, has been built into what Behrenbruch regards as roughly a US$1 billion opportunity in the United States over five years. A second prostate cancer imaging product, GaPP-1 (Gozetotide), received US approval and reimbursement in late 2025, which Behrenbruch expects to drive a further step-up in revenue alongside recent launches across 26 countries, including multiple European markets.
Behrenbruch points to a Phase III prostate cancer therapy as a major near-term clinical catalyst, with key data expected late 2026 or early 2027. He also highlights a broad pipeline of more than 14 molecules spanning prostate, renal and bladder cancer, with a paired strategy of developing both imaging and therapeutic products for each target to support earlier revenue generation and physician education.
Following the acquisition of the US radiopharmacy network RLS, which Behrenbruch says can reach 85% of the US population, Telix has shifted to a self-funded R&D model. He emphasises that profitability is being deferred as the company reinvests heavily ahead of anticipated first therapeutic launches in 2028 and expects multiple product approvals and catalysts to support the share price.
*Partner content
